Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gemme Bemoans ‘State Of Emergency’ In France

French Generics See Weak Growth And Biosimilars Need A Boost

Executive Summary

French off-patent industry association Gemme has declared a “state of emergency” for French generics as it revealed industry data for 2019 pointing to weak growth. Meanwhile, Gemme says, the country’s biosimilars market is “dynamic” and growing quickly but is still under-performing.

You may also be interested in...



French Market Survives On New Generics

After a year that French industry association Gemme says has demonstrated the importance of a sustainable generics sector, the market continued to grow purely due to the contribution made by newly genericized molecules.

French Body Favors Pharmacy Substitution For Biosimilars

French off-patent association Gemme has made a bold show of support for pharmacy-level biosimilar substitution in a position statement published by the industry body. However, the proposals run against the views of broader European industry association Medicines for Europe and come against the backdrop of recently-adopted French legislation that ensures doctors will be involved in biologic substitution.

French Law Tackles Biologic Originator Tactics

France is seeking to tackle the originator tactic of using low prices for biologic brands in hospitals to snare patients and keep them on the same product once they transition to outpatient care, where prices are much higher.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

GB149619

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel